---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-003776"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:32:07.664826+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa announces 2025 milestones and $377M cash position funding into 2028

## Summary
- Preliminary cash, equivalents, and securities of $377.0M as of Dec 31, 2024; funds operations into 2028.
- Initial Phase 1 SAD/MAD data for VAV1 degrader MRT-6160 expected Q1 2025; Novartis license deal gave $150M upfront.
- Updated biomarker and activity data from MRT-2359 Phase 1/2 in MYC-driven solid tumors expected Q1 2025.
- IND filing for NEK7 degrader MRT-8102 in H1 2025; CDK2 candidate nomination in H1 2025.
- Second-generation NEK7 candidate with CNS penetration nomination in H2 2025.

## SEC filing metadata
- accession: 0000950170-25-003776
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017025003776/0000950170-25-003776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017025003776/glue-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-003776
- JSON: https://secwatch.observer/filing/0000950170-25-003776.json
- Plain text: https://secwatch.observer/filing/0000950170-25-003776.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.